Why did Yiling Pharmaceutical suddenly plummet?

In 2022 12 and 19, Yiling pharmaceutical fell sharply from the opening and finally closed at the limit. Subsequently, the corresponding COVID-19 pharmaceutical concept stocks plummeted. Today, the overall market plummeted, and the Shanghai Stock Exchange fell-1.92%. Interestingly, COVID-19's pharmaceutical stocks rose the most recently, while real estate concept stocks fell the most.

Why stop at the limit? Mainly because of a rumor. It is rumored that Lianhua Qingwen will cause liver injury and liver failure, which is very harmful to the body. Subsequently, the company urgently issued the "Statement on the Safety of Lotus Clearing Pest".

In fact, normally, it's nothing, but shareholders can't bear it? Since September, there has been a sharp increase in epidemic cases, especially after the release of cold and fever-reducing drugs; Results Yiling Pharmaceutical rose from 18 to 53, nearly three times! ! Now it has formed a monster stock, which has attracted many speculators to chase after it from a high position.

Everyone knows that the first one is expensive, the second one is not clear about the company, and the third one has accumulated a lot of profit chips, so investors are still very anxious. At this time, Yiling's share price is often very sensitive. Once there is bad news, whether it is true or not, after timely clarification, it will inevitably plummet.

The supply of drugs in Beijing began to rise. In addition, most people start to work one after another after one week. The shortage of drugs in the future will not last long and will return to calm. So far, I think the popularity of pharmaceutical stocks in COVID-19 will decline in the future. We suggest staying away, so we should invest rationally and not blindly.

In fact, I began to be cautious half a month ago. Why? The reason is not complicated, it has gone up a lot.

The Central Economic Work Conference was held at the weekend, and many people gave high expectations. In fact, if you look closely, it is still a cliche to develop the economy and domestic demand. Stock trading is expected, and sometimes it really comes to this day, which is often a big drop. Just like this summer's new energy performance announcement period, many performances doubled, and the result fell sharply that day. So in today's market, I think it is still rising much, and there is a demand for profitable chips to be cashed.

Today, this decline is very terrible. In fact, if you look closely, it is mainly concentrated in the real estate and pharmaceutical sectors, which have risen too high during this period. These two sectors are also the main force of the recent market rise, and they are basically the realization of short-term profit chips. Most stocks didn't fall sharply.

I suggest that we can wait for the risk to be released in the short to medium term, which may be more difficult. If you don't invest enough, you need determination.

Yiling Pharmaceutical was established in 1992 and listed on the A-share market on July 201. Its main business is R&D, production and sales of patented innovative traditional Chinese medicines, among which Lianhua Qingwen series capsules/granules have attracted much attention because they have entered COVID-19 for many times.

According to the company, Lianhua Qingwen series capsules/granules are the first patented new drugs to explore the pathogenesis and treatment of exogenous fever by applying collateral disease theory, which can effectively inhibit bacteria, regulate immunity, relieve inflammation and fever, relieve cough and resolve phlegm. In April, 2020, the State Administration of Pharmaceutical Products approved Lianhua Qingwen Capsule/Granule to add a new indication of "novel coronavirus light ordinary type" on the basis of the original approved indication.

At present, Yiling Pharmaceutical has not directly disclosed the performance of Lianhua Qingwen. However, in the filing form of public investor relations activities on 10/0/28, Yiling Pharmaceutical mentioned that in the first three quarters of 2022, the sales revenue of the company's formula granule business increased well year-on-year. In a suggestive announcement on March 17 this year, Yiling pharmaceutical mentioned that in the first three quarters of 20021,the company realized an operating income of 3.37 billion yuan, accounting for 4 1.6% of the company's total operating income.